Uniting Wealth Partners’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Uniting Wealth Partners’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.41M	Buy	+67,858	New	+$4.69M	0.93%	28

Other funds holding XPH

Parkway Wealth Management Plano, Texas $869M AUM 25.74% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

First Citizens Bank & Trust Raleigh, North Carolina $6.73B AUM 18.92% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Measured Wealth Private Client Group Portsmouth, New Hampshire $398M AUM 22.66% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.87B AUM 19.94% 1-Year Est. Return

SVB Wealth Boston, Massachusetts $1.45B AUM 18.45% 1-Year Est. Return

Uniting Wealth Partners's XPH Position: Q3 2026 in Review

Uniting Wealth Partners opened a new position in State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2026: 67,858 shares worth $4.41M. The stake represents 0.93% of the portfolio and ranks #28 among its holdings.

62 funds tracked by Wall St. Rank hold XPH as of Q3 2026.

Uniting Wealth Partners held 67,858 shares of State Street SPDR S&P Pharmaceuticals ETF worth $4.41M as of Q3 2026.
State Street SPDR S&P Pharmaceuticals ETF was a new Uniting Wealth Partners position in Q3 2026.
State Street SPDR S&P Pharmaceuticals ETF made up 0.93% of Uniting Wealth Partners's portfolio in Q3 2026, its #28 holding.
62 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2026.

Based on Uniting Wealth Partners's 13F filing for Q3 2026, filed 6 Nov 2026.